Nature of the Event

This is a regulatory disclosure submitted to BSE Limited by Evonile Pharma Limited (formerly Novartis India Limited) (Scrip Code: 500672) on November 03, 2026. The submission is made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations. Its purpose is to provide an investor presentation for an earnings call scheduled for November 04, 2026, at 2:30 PM IST and to confirm that the presentation contains no unpublished price-sensitive information.

Key Quantitative Figures

Financial Performance for Q2 FY27 (₹ crore):

  • Revenue from operations: ₹56.1 (vs. ₹90.3 in Q2 FY26; -38% YoY)
  • Cost of goods sold: ₹47.1
  • Employee benefit expenses: ₹14.4 (vs. ₹5.3 in Q2 FY26; +171% YoY)
  • Other expenses: ₹11.0
  • Adjusted Operating EBITDA: (₹16.4)
  • One-time expenses: ₹15.4
  • Operating EBITDA: (₹31.8)
  • Operating EBITDA margin: -57%
  • Exceptional items: ₹68.3
  • EBITDA Post Exceptional Items: (₹100.1)
  • Depreciation & amortisation: ₹3.9
  • Finance costs: ₹4.8
  • Other income: ₹7.7
  • Profit/(Loss) before tax: (₹101.1)
  • Tax expenses: (₹23.6) [reversal]
  • Profit/(Loss) after tax: (₹77.5)

Financial Performance for H1 FY27 (₹ crore):

  • Revenue from operations: ₹159.9 (vs. ₹177.9 in H1 FY26; -10% YoY)
  • Cost of goods sold: ₹102.8
  • Employee benefit expenses: ₹19.1
  • Other expenses: ₹19.5
  • Adjusted Operating EBITDA: ₹18.5
  • One-time expenses: ₹15.4
  • Operating EBITDA: ₹3.1
  • Operating EBITDA margin: 2%
  • Exceptional items: ₹68.3
  • EBITDA Post Exceptional Items: (₹65.2)
  • Depreciation & amortisation: ₹4.3
  • Finance costs: ₹4.9
  • Other income: ₹16.5
  • Profit/(Loss) before tax: (₹57.9)
  • Tax expenses: (₹12.6) [reversal]
  • Profit/(Loss) after tax: (₹45.3)

Breakdown of Exceptional Items (₹68.3 crore):

  • ₹61 crore from the termination of exclusive promotion rights with one customer and related inventory purchase arrangements.
  • ₹7 crore relating to the unamortized import licences.

Other Financial Data:

  • The company had a net cash position as of March 2026 (amount not specified).
  • Finance cost of ~₹5 crore in Q2 FY27 is attributed to interest on borrowings for a brand acquisition in September 2026.

Dates of Action

  • Earnings Call Date: November 04, 2026, at 2:30 P.M. (IST)
  • Reference to Previous Intimation: October 26, 2026
  • Brand Acquisition: Completed in September 2026 (Minipress XL)

Parties or Entities Involved

  • Regulator Addressed: BSE Limited
  • Majority Shareholder: ChrysCapital Group (holds 70.68%)
  • Previous Parent/Related Entity: Novartis AG
  • Management: Dr. Vikas Gupta (Managing Director & CEO), Chandni Maru (Company Secretary and Compliance Officer), Bhagwat Singh Deora (Chief Financial Officer), Jason D'Souza (President – M&A, BD & IR)

Purpose or Stated Rationale

  • The submission is for the dissemination of an investor presentation for an upcoming earnings call.
  • The company is transitioning from a single-customer-dependent, outsourced distribution model to an independent operation with its own direct sales, marketing, and nationwide distribution network (20+ CFAs and 2000+ stockists). This shift is intended to unlock the untapped potential of its legacy brands (Voveran, Methergin, Calcium Sandoz, etc.).
  • The transition involves a complete organizational and infrastructure build-out, including establishing accounting, HRMS, and field reporting systems.

Financial or Operational Impact

  • The change in business model has led to a one-time revenue correction, making Q2 FY27 sales not comparable with Q2 FY26.
  • The transition has resulted in one-time expenses (~₹15.4 crore) and higher operational expenses (e.g., employee costs up 171% YoY in Q2).
  • The company expects its actual cost structure to be reflected in Q4 FY27 / Q1 FY28.

Capital Structure Impact

  • ChrysCapital Group holds a 70.68% stake in the company. No other changes to the capital structure are disclosed in this document.

Strategic Updates & Forward-Looking Commentary

  • Completed Transactions: The company acquired the Minipress XL brand and in-licensed an ophthalmology portfolio, adding cardiology and ophthalmology to its therapy areas.
  • Key Imperatives for FY27:

1. Stabilize and scale the business by reestablishing market availability and prescriber mindshare.

2. Complete the infrastructure build-out, with the full organizational build-out targeted for completion by Q4 FY27.

3. Return to growth across the portfolio, including reigniting legacy brands and leveraging the new field force and distribution.

  • Long-Term Vision: To establish Evonile as one of India's progressive and forward-looking domestic pharmaceutical companies.